Royalty Pharma Q1 2022 Earnings Report
Key Takeaways
Royalty Pharma reported a decrease in net cash provided by operating activities to $460 million, while total income and other revenues decreased 2% to $562 million. However, Adjusted Cash Receipts increased 15% to $605 million and Adjusted EBITDA grew 15% to $556 million. The company reaffirmed its 2022 Adjusted Cash Receipts guidance of $2,225 million to $2,300 million.
Adjusted Cash Receipts increased 15% to $605 million, driven by cystic fibrosis franchise, Tysabri and recent royalty acquisitions.
Adjusted EBITDA grew 15% to $556 million, driven by strong growth in Adjusted Cash Receipts.
Announced transactions of up to $450 million in Q1 2022, including an expanded partnership with Cytokinetics.
2022 guidance reaffirmed: Adjusted Cash Receipts expected to be $2,225 to $2,300 million.
Royalty Pharma
Royalty Pharma
Forward Guidance
Royalty Pharma reaffirmed its 2022 Adjusted Cash Receipts guidance of $2,225 million to $2,300 million, excluding new transactions announced after the date of this release.